Volume 13, Issue 4 (2023)                   JMBS 2023, 13(4): 0-0 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

rojhannezhad M, Behmanesh M, Nikravesh A, Naser Moghadasi A. Effect of TUG1 non-coding RNA knockdown on CD20 receptor expression. JMBS 2023; 13 (4)
URL: http://biot.modares.ac.ir/article-22-60906-en.html
1- Tarbiat Modares university, Faculty of Biological Sciences, Genetics department, PhD student of Genetics
2- Department of Genetics,Faculty of Biological Science, TarbiatModares University, Tehran, Iran, Tehran, Jalal Al-Ahmad St., Tarbiat Modares University , behmanesh@modares.ac.ir
3- Associate Professor of Molecular GeneticsDepartment of Advanced Technologies, School of MedicineNorth Khorasan University of Medical Sciences, North Khorasan University of Medical Sciences, Bojnurd, Iran,
4- Assistant Professor of NeurologyDepartment of Neurology, School of MedicineMultiple Sclerosis Research CenterSina HospitalTehran University of Medical Sciences, Tehran University of Medical Sciences
Abstract:   (650 Views)
 Multiple sclerosis (MS) is one of the most common autoimmune diseases in Iran and the world. To date, many drugs have been developed to control the progression of MS as a chronic inflammatory disease of the central nervous system. Rituximab is a chimeric mouse-human monoclonal antibody that binds to the CD20 receptor on the surface of B cells and induces apoptosis. Today, Numerous studies have confirmed the increasing role of non-coding RNAs in regulating the expression of genes and molecular processes, including apoptosis. Furthermore, bioinformatic analysis results indicate that TUG1 LncRNA is differentially expressed in MS patients. Thus, In the present study the possible role of TUG1 in regulating rituximab mechanism of action and apoptosis induction was experimentally investigated. To do this, specific DNAzyme against TUG1 was designed and transfected into Raji cells in the presence or absence of the drug. After transfection, RNA extraction and cDNA synthesis were performed. Then, the expression of target genes was examined by Real-Time PCR technique. The results showed an increase in CD20 expression and a decrease in SMAD2 expression levels. Furthermore, decreased TUG1 gene expression led to an increase in apoptosis and cell accumulation in the G1 phase. It seems that TUG1 expression level can play a significant role in CD20 expression in B cells and therefore on the therapeutic efficacy of rituximab.
 
Full-Text [PDF 1140 kb]   (219 Downloads)    
Article Type: Original Research | Subject: Molecular biotechnology
Received: 2022/04/16 | Accepted: 2022/09/6 | Published: 2023/11/19

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.